These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 14962276)

  • 1. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum.
    Walpen AJ; Laumonier T; Aebi C; Mohacsi PJ; Rieben R
    Xenotransplantation; 2004 Mar; 11(2):141-8. PubMed ID: 14962276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgM-enriched human introvenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies.
    Roos A; Rieben R; Faber-Krol MC; Daha MR
    Xenotransplantation; 2003 Nov; 10(6):596-605. PubMed ID: 14708528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.
    Rieben R; Roos A; Muizert Y; Tinguely C; Gerritsen AF; Daha MR
    Blood; 1999 Feb; 93(3):942-51. PubMed ID: 9920844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN.
    Piepers S; Jansen MD; Cats EA; van Sorge NM; van den Berg LH; van der Pol WL
    J Neuroimmunol; 2010 Dec; 229(1-2):256-62. PubMed ID: 20920831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
    Wagner E; Platt JL; Frank MM
    J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
    Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood.
    Banz Y; Cung T; Korchagina EY; Bovin NV; Haeberli A; Rieben R
    Xenotransplantation; 2005 Nov; 12(6):434-43. PubMed ID: 16202066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells.
    Duvall MR; Hwang HY; Boackle RJ
    Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells.
    Laumonier T; Walpen AJ; Maurus CF; Mohacsi PJ; Matozan KM; Korchagina EY; Bovin NV; Vanhove B; Seebach JD; Rieben R
    Transplantation; 2003 Sep; 76(5):838-43. PubMed ID: 14501864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
    Miletic VD; Hester CG; Frank MM
    J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver.
    Fierer J; Finley F
    J Clin Invest; 1979 May; 63(5):912-921. PubMed ID: 376551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.
    Tarr PI; Hosea SW; Brown EJ; Schneerson R; Sutton A; Frank MM
    J Immunol; 1982 Apr; 128(4):1772-5. PubMed ID: 6977569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-complement effects of lactoferrin-derived peptides.
    Samuelsen Ø; Haukland HH; Ulvatne H; Vorland LH
    FEMS Immunol Med Microbiol; 2004 Jun; 41(2):141-8. PubMed ID: 15145458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Opsonizing activity of human immunoglobulin preparations for intravenous use (IVIG)].
    Banach W; Bucholc B
    Med Dosw Mikrobiol; 1994; 46(4):349-55. PubMed ID: 7603135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
    Tesh VL; Duncan RL; Morrison DC
    J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. An in vivo and in vitro evaluation.
    Gautreau C; Kojima T; Woimant G; Cardoso J; Devillier P; Houssin D
    Transplantation; 1995 Nov; 60(9):903-7. PubMed ID: 7491691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the alternative pathway of complement in hyperacute xenograft rejection of rabbit hearts by human blood.
    Forty J; White DJ; Wallwork J
    J Heart Lung Transplant; 1993; 12(2):283-6; discussion 286-7. PubMed ID: 8476902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the interaction of C1q with immunoglobulins and the classical pathway of complement activation by steroids and triterpenoids sulfates.
    Bureeva S; Andia-Pravdivy J; Symon A; Bichucher A; Moskaleva V; Popenko V; Shpak A; Shvets V; Kozlov L; Kaplun A
    Bioorg Med Chem; 2007 May; 15(10):3489-98. PubMed ID: 17383882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-capsular antibodies activate killing of Escherichia coli O8:K87 by the alternate complement pathway in porcine serum.
    Clark NM; Berberov EM; Wang M; Moxley RA
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):185-91. PubMed ID: 16919781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.